PE20180162A1 - Polipeptidos dirigidos a la fusion de vih - Google Patents
Polipeptidos dirigidos a la fusion de vihInfo
- Publication number
- PE20180162A1 PE20180162A1 PE2017002311A PE2017002311A PE20180162A1 PE 20180162 A1 PE20180162 A1 PE 20180162A1 PE 2017002311 A PE2017002311 A PE 2017002311A PE 2017002311 A PE2017002311 A PE 2017002311A PE 20180162 A1 PE20180162 A1 PE 20180162A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- polypeptides
- hiv fusion
- targeting hiv
- sequence
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000004927 fusion Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 4
- 102000016359 Fibronectins Human genes 0.000 abstract 2
- 108010067306 Fibronectins Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101150048348 GP41 gene Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Abstract
SE REFIERE A POLIPEPTIDOS QUE COMPRENDEN TRES DOMINIOS ACTIVOS QUE SON: A) UNA PROTEINA DEL DOMINIO DE SOPORTE A BASE DE FIBRONECTINA QUE SE FIJA A CD4 CUYA SECUENCIA DE AMINOACIDOS ES LA SEQ ID N°: 95-114; B) UNA PROTEINA DEL DOMINIO DE SOPORTE A BASE DE FIBRONECTINA QUE SE FIJA AL DOMINIO N17 DE GP41 CUYA SECUENCIA DE AMINOACIDOS ES LA SEQ ID N°: 115-371; Y C) UN INHIBIDOR PEPTIDICO DE LA FUSION DE VIH CUYA SECUENCIA DE AMINOACIDOS ES LA SEQ ID N°: 372-392; EN DONDE DICHO POLIPEPTIDO COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID N°: 3-10. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS POLIPEPTIDOS SON UTILES PARA TRATAR EL VIH
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562152271P | 2015-04-24 | 2015-04-24 | |
| US201562257474P | 2015-11-19 | 2015-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180162A1 true PE20180162A1 (es) | 2018-01-18 |
Family
ID=55809237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002311A PE20180162A1 (es) | 2015-04-24 | 2016-04-14 | Polipeptidos dirigidos a la fusion de vih |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10407490B2 (es) |
| EP (2) | EP3985020A1 (es) |
| JP (3) | JP6894846B2 (es) |
| KR (1) | KR20170138558A (es) |
| CN (1) | CN107922474A (es) |
| AU (2) | AU2016252008B2 (es) |
| BR (1) | BR112017022790A2 (es) |
| CA (1) | CA2983276A1 (es) |
| CL (1) | CL2017002687A1 (es) |
| CO (1) | CO2017011583A2 (es) |
| CR (1) | CR20170482A (es) |
| DO (1) | DOP2017000246A (es) |
| EA (1) | EA035332B1 (es) |
| ES (1) | ES2884267T3 (es) |
| HK (1) | HK1243432A1 (es) |
| IL (1) | IL255122A0 (es) |
| MA (2) | MA56222A (es) |
| MX (1) | MX2017013687A (es) |
| PE (1) | PE20180162A1 (es) |
| PH (1) | PH12017501914A1 (es) |
| PT (1) | PT3286212T (es) |
| SG (1) | SG11201708441RA (es) |
| TW (1) | TW201643185A (es) |
| UY (1) | UY36650A (es) |
| WO (1) | WO2016171980A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755100A (zh) * | 2017-02-20 | 2017-05-31 | 李因传 | 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统 |
| WO2019123262A1 (en) | 2017-12-18 | 2019-06-27 | VIIV Healthcare UK (No.5) Limited | Antigen binding polypeptides |
| CN108997482B (zh) * | 2018-08-09 | 2025-09-09 | 东莞市朋志生物科技有限公司 | 用于检测hiv-1的合成肽 |
| WO2021081515A2 (en) * | 2019-10-25 | 2021-04-29 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| CN117980465A (zh) * | 2021-08-30 | 2024-05-03 | 康霖生物科技（杭州）有限公司 | 一种用于艾滋病病毒感染基因治疗的基因序列构建体 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| RU2233878C2 (ru) | 1997-01-21 | 2004-08-10 | Дзе Дженерал Хоспитал Корпорейшн | Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2265701A (en) * | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| EP2385067A1 (en) | 2000-07-11 | 2011-11-09 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| CN100341573C (zh) * | 2002-09-27 | 2007-10-10 | 唐纳士公司 | 用于预防和治疗获得性免疫缺陷综合症的协同组合物 |
| ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CL2008002092A1 (es) | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
| BRPI0821924A2 (pt) | 2007-12-27 | 2015-07-07 | Novartis Ag | Moléculas de ligação baseadas em fibronectina melhoradas e seu uso |
| JP6192891B2 (ja) | 2008-05-02 | 2017-09-06 | ノバルティス アーゲー | 改善されたフィブロネクチンベースの結合分子およびそれらの使用 |
| EP3128048B1 (en) * | 2008-10-31 | 2018-11-28 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| WO2011077093A1 (en) * | 2009-12-22 | 2011-06-30 | Aarhus Universitet | Bivalent molecules for hiv entry inhibition |
| MX2012011781A (es) * | 2010-04-13 | 2012-11-16 | Squibb Bristol Myers Co | Proteinas de dominio de armazon basadas en fibronectina que se unen a la proteina convertasa subtilisina kexina tipo q (pcsk9). |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| JP6145404B2 (ja) * | 2010-05-07 | 2017-06-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エクスビボでの細胞の検出のための診断的方法 |
| US9260496B2 (en) * | 2010-12-22 | 2016-02-16 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
| CA2834577A1 (en) * | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| CN103827361A (zh) * | 2011-09-27 | 2014-05-28 | 詹森生物科技公司 | 具有可供选择的结合表面的基于iii型纤连蛋白重复的蛋白质支架 |
| US20150361159A1 (en) * | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| EP2968587A2 (en) * | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| CN103333255A (zh) | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
-
2016
- 2016-04-14 MA MA056222A patent/MA56222A/fr unknown
- 2016-04-14 JP JP2017555557A patent/JP6894846B2/ja active Active
- 2016-04-14 ES ES16718817T patent/ES2884267T3/es active Active
- 2016-04-14 BR BR112017022790-8A patent/BR112017022790A2/pt not_active IP Right Cessation
- 2016-04-14 US US15/568,830 patent/US10407490B2/en active Active
- 2016-04-14 EA EA201792269A patent/EA035332B1/ru not_active IP Right Cessation
- 2016-04-14 PE PE2017002311A patent/PE20180162A1/es unknown
- 2016-04-14 MX MX2017013687A patent/MX2017013687A/es unknown
- 2016-04-14 CN CN201680036930.XA patent/CN107922474A/zh active Pending
- 2016-04-14 MA MA041943A patent/MA41943A/fr unknown
- 2016-04-14 HK HK18102882.7A patent/HK1243432A1/zh unknown
- 2016-04-14 CA CA2983276A patent/CA2983276A1/en not_active Abandoned
- 2016-04-14 EP EP21176464.2A patent/EP3985020A1/en not_active Withdrawn
- 2016-04-14 SG SG11201708441RA patent/SG11201708441RA/en unknown
- 2016-04-14 KR KR1020177033985A patent/KR20170138558A/ko not_active Withdrawn
- 2016-04-14 PT PT167188176T patent/PT3286212T/pt unknown
- 2016-04-14 WO PCT/US2016/027424 patent/WO2016171980A1/en not_active Ceased
- 2016-04-14 CR CR20170482A patent/CR20170482A/es unknown
- 2016-04-14 AU AU2016252008A patent/AU2016252008B2/en not_active Ceased
- 2016-04-14 EP EP16718817.6A patent/EP3286212B1/en active Active
- 2016-04-22 TW TW105112708A patent/TW201643185A/zh unknown
- 2016-04-22 UY UY0001036650A patent/UY36650A/es not_active Application Discontinuation
-
2017
- 2017-10-18 IL IL255122A patent/IL255122A0/en unknown
- 2017-10-19 PH PH12017501914A patent/PH12017501914A1/en unknown
- 2017-10-23 CL CL2017002687A patent/CL2017002687A1/es unknown
- 2017-10-23 DO DO2017000246A patent/DOP2017000246A/es unknown
- 2017-11-14 CO CONC2017/0011583A patent/CO2017011583A2/es unknown
-
2019
- 2019-08-07 US US16/533,941 patent/US11155602B2/en active Active
- 2019-09-06 AU AU2019226255A patent/AU2019226255A1/en not_active Abandoned
-
2020
- 2020-10-16 JP JP2020174288A patent/JP2021035951A/ja active Pending
-
2023
- 2023-02-03 JP JP2023014947A patent/JP7465378B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001000A1 (es) | Proteínas de fusión fc heterodiméricas il15/il15ralfa | |
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| UY40283A (es) | Método para alterar una propiedad de una planta | |
| PE20180162A1 (es) | Polipeptidos dirigidos a la fusion de vih | |
| CL2018003148A1 (es) | Proteínas de fusión y usos de las mismas. | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| PE20170471A1 (es) | Polipeptidos receptores formulados y metodos relacionados | |
| ES2682981T3 (es) | Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas | |
| CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| UY36965A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| MX389878B (es) | Proteinas quimericas de factor viii y usos de estas. | |
| MX2014006396A (es) | Vacunas contra el virus de la influenza y sus usos. | |
| AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| EA201592306A1 (ru) | Вакцины против вируса гриппа и их применения | |
| CL2016001405A1 (es) | A peptide mixture | |
| UY35462A (es) | Formulación de un polipéptido del factor viii. | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| PE20170290A1 (es) | Vacunas contra virus de influenza y usos de las mismas | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. |